Market Cap 126.12M
Revenue (ttm) 0.00
Net Income (ttm) -61.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,481,200
Avg Vol 1,276,366
Day's Range N/A - N/A
Shares Out 72.48M
Stochastic %K 17%
Beta -0.23
Analysts Strong Sell
Price Target $7.00

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, whic...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 980 9099
Address:
1599 Industrial Road, San Carlos, United States
Issidur
Issidur Sep. 14 at 6:51 AM
0 · Reply
Creisi
Creisi Sep. 14 at 3:54 AM
$BMEA Mick is teamed with Dr. Frías, CMO of BMEA who didn't just casually work on Lilly’s metabolic pipeline, he was the lead investigator who helped run the clinical trials that built Lilly's trillion-dollar metabolic empire including Mounjaro and Zepbound... Oh, and by the way, he also ran the trials for Novo's Ozempic/Wegovy. He is the lead author for the major medical articles on both Lilly's and Novo's entire Billion dollar obesity franchises. & Mick didn't stop there.. Mick also brought in Dr. Kirschberg as BMF-650 program lead & the primary chemical mind behind BMEA's covalent platform. He shares the same corporate pedigree as Mick, having served as Senior Director of Chemistry at Gilead. Kirschberg specializes in small-molecule design and optimization just as he did with curing AIDS, Hepatitis, etc., He was brought into BMEA specifically to engineer oral small molecules with highly optimized oral bioavailability and linear pharmacokinetic profiles. "Bet on Mick"
2 · Reply
Bigpapa46
Bigpapa46 Sep. 14 at 12:20 AM
$BMEA well the nasdaq is getting torched in overnight trading due to AI slow down concerns. lol. that’s not going to happen, traders always need something to worry about.
2 · Reply
Jkm11
Jkm11 Sep. 13 at 10:56 PM
$BMEA drop it mick
0 · Reply
perplex
perplex Sep. 13 at 7:50 PM
$BMEA Tomorrow?..
1 · Reply
Hunchinvestor
Hunchinvestor Sep. 13 at 6:08 PM
0 · Reply
B34Rhunter
B34Rhunter Sep. 13 at 4:51 PM
$BMEA data window is getting smaller and smaller, good time to have a bag, staying long and staying
0 · Reply
Creisi
Creisi Sep. 12 at 4:00 PM
$BMEA Total short interest remains fixed at 11.95 million shares, meaning a massive 18.44% of BMEA's public float is sold short. If Mick releases the Medpace data pre-market, short-sellers face a severe lack of exit liquidity. Because call options dominated Friday’s afternoon volume while put volume remained near zero, options market makers are heading into the weekend heavily short gamma. Any pre-market spike past $2.00 next week will force MM's to buy underlying stock to hedge their liabilities, adding immediate buying pressure to the squeeze. This is going to go off, one way or another, as soon as the data drops.
1 · Reply
Creisi
Creisi Sep. 12 at 3:23 PM
$BMEA 100%. Big Pharma are not stupid. The reality is this launch validates Icovamenib immediately allowing Mick yo utilize the very vehicle he developed to mitigate a buyout that fully valued Icovamenib through those very CVR's. If anyone can make this a massive win for BMEA, Muck is the man! BET ON MICK!
1 · Reply
septrading
septrading Sep. 12 at 1:19 PM
$BMEA Further thoughts on the KURA spinoff, after looking into BVF's involvement and the highly promotional commentary being put out by CEO Troy Wilson in the BioPharma Dive interview, where he's trying to tamp down our 2-3 year clinical lead by suggesting they have a safety advantage. It's actually stepping right up to the line of defamation. Our clinical evidence actually shows the opposite, and he has no evidence whatsover on which to base his own safety claims. It's a rhetorical trick to suggest that with Lilly's involvement they are the superior commercial product for chronic use. He gets a two-fer by excusing being a late entrant and also making "optimized for chronic use" sound like a clinical conclusion. It is not. Lilly's involvement lends credibility to a proposition that remains experimentally incomplete, and will be for years. Regarding BVF, they were already in KURA for a hefty 8.445M shares, or 9.5%, so this new money is a rounding error. They were previously holding 3.9% of SNDX (the other non-covalent menin inhibitor) years ago, but sold out. What will be telling is what the KURA/Caspian scientists actually say on this front on September 29th at EASD. Will they try to present actual safety differentiation evidence, or simply repeat the claim without it?
1 · Reply
Latest News on BMEA
Biomea Fusion to Participate in Upcoming Investor Conferences

Sep 3, 2026, 8:00 AM EDT - 10 days ago

Biomea Fusion to Participate in Upcoming Investor Conferences


Biomea Fusion completes enrollment in COVALENT-211 trial

2026-08-24T11:15:22.000Z - 20 days ago

Biomea Fusion completes enrollment in COVALENT-211 trial


Biomea Fusion doses first patient in OPAL study

2026-08-17T07:38:07.000Z - 4 weeks ago

Biomea Fusion doses first patient in OPAL study


Biomea Fusion price target lowered to $7 from $9 at Citizens

2026-08-06T19:25:43.000Z - 5 weeks ago

Biomea Fusion price target lowered to $7 from $9 at Citizens


Biomea Fusion reports Q2 EPS (12c), consensus (23c)

2026-08-05T21:35:44.000Z - 5 weeks ago

Biomea Fusion reports Q2 EPS (12c), consensus (23c)


Biomea Fusion Slides: Corporate presentation

Aug 5, 2026, 4:00 PM EDT - 5 weeks ago

Biomea Fusion Slides: Corporate presentation


Biomea Fusion Quarterly report: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 5 weeks ago

Biomea Fusion Quarterly report: Q2 2026


Biomea Fusion Earnings release: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 5 weeks ago

Biomea Fusion Earnings release: Q2 2026


Biomea Fusion Slides: Corporate presentation

Jul 1, 2026, 8:00 AM EDT - 2 months ago

Biomea Fusion Slides: Corporate presentation


Biomea Fusion Transcript: AGM 2026

Jun 10, 2026, 1:00 PM EDT - 3 months ago

Biomea Fusion Transcript: AGM 2026


Biomea Fusion management to meet with Citizens

2026-06-04T19:41:19.000Z - 3 months ago

Biomea Fusion management to meet with Citizens


Biomea Fusion Slides: Corporate presentation

May 29, 2026, 7:00 AM EDT - 3 months ago

Biomea Fusion Slides: Corporate presentation


Biomea Fusion to Participate at Upcoming Investor Conferences

May 12, 2026, 4:05 PM EDT - 4 months ago

Biomea Fusion to Participate at Upcoming Investor Conferences


Biomea Fusion reports Q1 EPS (17c), consensus (19c)

2026-05-11T23:09:08.000Z - 4 months ago

Biomea Fusion reports Q1 EPS (17c), consensus (19c)


Biomea Fusion Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 4 months ago

Biomea Fusion Quarterly report: Q1 2026


Biomea Fusion Earnings release: Q1 2026

May 11, 2026, 7:00 AM EDT - 4 months ago

Biomea Fusion Earnings release: Q1 2026


Biomea Fusion Transcript: Status update

May 5, 2026, 2:30 PM EDT - 4 months ago

Biomea Fusion Transcript: Status update


Biomea Fusion initiated with an Outperform at Citizens

2026-05-05T08:25:12.000Z - 4 months ago

Biomea Fusion initiated with an Outperform at Citizens


Biomea Fusion Transcript: Study result

Apr 28, 2026, 8:30 AM EDT - 4 months ago

Biomea Fusion Transcript: Study result


Biomea Fusion Press release: Study result

Apr 28, 2026, 8:30 AM EDT - 4 months ago

Biomea Fusion Press release: Study result


Biomea Fusion Slides: Study result

Apr 28, 2026, 8:30 AM EDT - 4 months ago

Biomea Fusion Slides: Study result


Biomea Fusion Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Biomea Fusion Proxy statement: Proxy filing


Biomea Fusion Slides: Corporate presentation

Apr 21, 2026, 7:00 AM EDT - 4 months ago

Biomea Fusion Slides: Corporate presentation


Biomea Fusion Transcript: Fireside chat

Mar 30, 2026, 3:00 PM EDT - 5 months ago

Biomea Fusion Transcript: Fireside chat


Biomea Fusion Transcript: Fireside chat

Mar 30, 2026, 1:00 PM EDT - 5 months ago

Biomea Fusion Transcript: Fireside chat


Biomea Fusion Annual report: Q4 2025

Mar 24, 2026, 4:00 PM EDT - 5 months ago

Biomea Fusion Annual report: Q4 2025


Biomea Fusion Earnings release: Q4 2025

Mar 24, 2026, 4:00 PM EDT - 5 months ago

Biomea Fusion Earnings release: Q4 2025


Biomea Fusion management to meet virtually with Craig-Hallum

2026-03-04T15:46:54.000Z - 6 months ago

Biomea Fusion management to meet virtually with Craig-Hallum


Biomea Fusion Slides: Corporate presentation

Feb 24, 2026, 7:00 AM EST - 6 months ago

Biomea Fusion Slides: Corporate presentation


Biomea Fusion initiated with a Buy at Rodman & Renshaw

2026-01-13T20:20:23.000Z - 8 months ago

Biomea Fusion initiated with a Buy at Rodman & Renshaw


Biomea Fusion Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 8 months ago

Biomea Fusion Slides: Corporate presentation


Biomea Fusion Slides: Corporate Presentation

Nov 18, 2025, 7:00 AM EST - 9 months ago

Biomea Fusion Slides: Corporate Presentation


Biomea Fusion Earnings release: Q3 2025

Nov 4, 2025, 4:00 PM EST - 10 months ago

Biomea Fusion Earnings release: Q3 2025


Biomea Fusion Quarterly report: Q3 2025

Nov 4, 2025, 4:00 PM EST - 10 months ago

Biomea Fusion Quarterly report: Q3 2025


Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

Oct 30, 2025, 8:00 AM EDT - 10 months ago

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025


Biomea Fusion Transcript: Study Result

Oct 7, 2025, 8:30 AM EDT - 11 months ago

Biomea Fusion Transcript: Study Result


Biomea Fusion Press release: Study Result

Oct 7, 2025, 8:30 AM EDT - 11 months ago

Biomea Fusion Press release: Study Result


Biomea Fusion Slides: Study Result

Oct 7, 2025, 8:30 AM EDT - 11 months ago

Biomea Fusion Slides: Study Result


Biomea Fusion Announces Pricing of Public Offering of Securities

Oct 7, 2025, 8:00 AM EDT - 11 months ago

Biomea Fusion Announces Pricing of Public Offering of Securities


Biomea Fusion Announces Proposed Public Offering of Securities

Oct 6, 2025, 4:18 PM EDT - 11 months ago

Biomea Fusion Announces Proposed Public Offering of Securities


Biomea Fusion Registration statement: Registration Filing

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Biomea Fusion Registration statement: Registration Filing


Biomea Fusion Earnings release: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Biomea Fusion Earnings release: Q2 2025


Biomea Fusion Quarterly report: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Biomea Fusion Quarterly report: Q2 2025


Biomea Fusion Slides: Investor Presentation

Jun 23, 2025, 11:00 AM EDT - 1 year ago

Biomea Fusion Slides: Investor Presentation


Stocks to Watch: Biomea Fusion, Bitdeer Technologies

Jun 17, 2025, 7:28 PM EDT - 1 year ago

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

BTDR


Biomea Fusion Quarterly report: Q1 2025

May 5, 2025, 4:00 PM EDT - 1 year ago

Biomea Fusion Quarterly report: Q1 2025


Biomea Fusion Earnings release: Q1 2025

May 5, 2025, 4:00 PM EDT - 1 year ago

Biomea Fusion Earnings release: Q1 2025


Biomea Fusion Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Biomea Fusion Proxy statement: Proxy Filing


Biomea Fusion Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Biomea Fusion Proxy statement: Proxy Filing


Biomea Fusion Annual report: Q4 2024

Mar 31, 2025, 4:00 PM EDT - 1 year ago

Biomea Fusion Annual report: Q4 2024


Biomea Fusion Earnings release: Q4 2024

Mar 31, 2025, 4:00 PM EDT - 1 year ago

Biomea Fusion Earnings release: Q4 2024


Biomea Fusion Announces Leadership Transition

Mar 25, 2025, 7:00 PM EDT - 1 year ago

Biomea Fusion Announces Leadership Transition


Biomea Fusion Transcript: Status Update

Mar 19, 2025, 1:00 PM EDT - 1 year ago

Biomea Fusion Transcript: Status Update


Biomea Fusion Slides: FY 2025

Jan 15, 2025, 4:30 PM EST - 1 year ago

Biomea Fusion Slides: FY 2025


Biomea Fusion Transcript: Study Result

Dec 17, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion Transcript: Study Result


Biomea Fusion Press release: Study Result

Dec 17, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion Press release: Study Result


Biomea Fusion Slides: Study Result

Dec 17, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion Slides: Study Result


Biomea Fusion Transcript: Study Update

Dec 9, 2024, 4:30 PM EST - 1 year ago

Biomea Fusion Transcript: Study Update


Biomea Fusion Press release: Study Update

Dec 9, 2024, 4:30 PM EST - 1 year ago

Biomea Fusion Press release: Study Update


Biomea Fusion Slides: Study Update

Dec 9, 2024, 4:30 PM EST - 1 year ago

Biomea Fusion Slides: Study Update


Issidur
Issidur Sep. 14 at 6:51 AM
0 · Reply
Creisi
Creisi Sep. 14 at 3:54 AM
$BMEA Mick is teamed with Dr. Frías, CMO of BMEA who didn't just casually work on Lilly’s metabolic pipeline, he was the lead investigator who helped run the clinical trials that built Lilly's trillion-dollar metabolic empire including Mounjaro and Zepbound... Oh, and by the way, he also ran the trials for Novo's Ozempic/Wegovy. He is the lead author for the major medical articles on both Lilly's and Novo's entire Billion dollar obesity franchises. & Mick didn't stop there.. Mick also brought in Dr. Kirschberg as BMF-650 program lead & the primary chemical mind behind BMEA's covalent platform. He shares the same corporate pedigree as Mick, having served as Senior Director of Chemistry at Gilead. Kirschberg specializes in small-molecule design and optimization just as he did with curing AIDS, Hepatitis, etc., He was brought into BMEA specifically to engineer oral small molecules with highly optimized oral bioavailability and linear pharmacokinetic profiles. "Bet on Mick"
2 · Reply
Bigpapa46
Bigpapa46 Sep. 14 at 12:20 AM
$BMEA well the nasdaq is getting torched in overnight trading due to AI slow down concerns. lol. that’s not going to happen, traders always need something to worry about.
2 · Reply
Jkm11
Jkm11 Sep. 13 at 10:56 PM
$BMEA drop it mick
0 · Reply
perplex
perplex Sep. 13 at 7:50 PM
$BMEA Tomorrow?..
1 · Reply
Hunchinvestor
Hunchinvestor Sep. 13 at 6:08 PM
0 · Reply
B34Rhunter
B34Rhunter Sep. 13 at 4:51 PM
$BMEA data window is getting smaller and smaller, good time to have a bag, staying long and staying
0 · Reply
Creisi
Creisi Sep. 12 at 4:00 PM
$BMEA Total short interest remains fixed at 11.95 million shares, meaning a massive 18.44% of BMEA's public float is sold short. If Mick releases the Medpace data pre-market, short-sellers face a severe lack of exit liquidity. Because call options dominated Friday’s afternoon volume while put volume remained near zero, options market makers are heading into the weekend heavily short gamma. Any pre-market spike past $2.00 next week will force MM's to buy underlying stock to hedge their liabilities, adding immediate buying pressure to the squeeze. This is going to go off, one way or another, as soon as the data drops.
1 · Reply
Creisi
Creisi Sep. 12 at 3:23 PM
$BMEA 100%. Big Pharma are not stupid. The reality is this launch validates Icovamenib immediately allowing Mick yo utilize the very vehicle he developed to mitigate a buyout that fully valued Icovamenib through those very CVR's. If anyone can make this a massive win for BMEA, Muck is the man! BET ON MICK!
1 · Reply
septrading
septrading Sep. 12 at 1:19 PM
$BMEA Further thoughts on the KURA spinoff, after looking into BVF's involvement and the highly promotional commentary being put out by CEO Troy Wilson in the BioPharma Dive interview, where he's trying to tamp down our 2-3 year clinical lead by suggesting they have a safety advantage. It's actually stepping right up to the line of defamation. Our clinical evidence actually shows the opposite, and he has no evidence whatsover on which to base his own safety claims. It's a rhetorical trick to suggest that with Lilly's involvement they are the superior commercial product for chronic use. He gets a two-fer by excusing being a late entrant and also making "optimized for chronic use" sound like a clinical conclusion. It is not. Lilly's involvement lends credibility to a proposition that remains experimentally incomplete, and will be for years. Regarding BVF, they were already in KURA for a hefty 8.445M shares, or 9.5%, so this new money is a rounding error. They were previously holding 3.9% of SNDX (the other non-covalent menin inhibitor) years ago, but sold out. What will be telling is what the KURA/Caspian scientists actually say on this front on September 29th at EASD. Will they try to present actual safety differentiation evidence, or simply repeat the claim without it?
1 · Reply
Jkm11
Jkm11 Sep. 12 at 7:40 AM
$BMEA super excited to see what transpires the next few weeks with BMEA. Lets roll!
0 · Reply
Bullworks
Bullworks Sep. 11 at 9:01 PM
$BMEA had a hope for after hours but early next week hopefully !
0 · Reply
Creisi
Creisi Sep. 11 at 8:58 PM
$BMEA At Gilead, Mick's historical success was built on optimizing the value of oral small molecules during clinical phases. He understands that an early-stage company captures its highest margin of return for shareholders by selling a validated, de-risked platform to a corporate buyer with an existing, global distribution infrastructure. He wrote the book on M&A and using CVR's to make them happen asap. With over 82% of his compensation tied directly to options and equity, a multi-billion-dollar acquisition from Lilly, Pfizer, Sanof, etc., completely accelerates his wealth generation. If he engineers a buyout his equity structure provides an immediate payout of extreme wealth; which no matter who you are, is a massive motivator. He didn't come back to tarnish his stellar reputation, he came back to extend the mythical legacy.
1 · Reply
2duhmooon
2duhmooon Sep. 11 at 8:22 PM
2 · Reply
DreiMark
DreiMark Sep. 11 at 8:04 PM
0 · Reply
Bigpapa46
Bigpapa46 Sep. 11 at 8:03 PM
$BMEA Shorts still have control for now
0 · Reply
Creisi
Creisi Sep. 11 at 7:58 PM
$BMEA Forget the science, forget the data, forget all detailed drug development.... Think about it? Does it make any sense for a 75 yr old Big Pharma High Level Executive Vet with his name splattered all over Med Schools, and history journals,l; the very guy who developed cures for the world's largest afflictions such as AIDS, Hepatitis, etc.;.... come out of retirement after 7 years to deliver a market flop from a tiny CP company. The guy whose credibility, fame & financial position is off the charts. Does it make any sense for him to come back to a struggling tiny clinical biopharma company to literally destroy his own legacy by dropping data that's at best, "good enough"...???? No fuckin' way! Or does it make far more sense that he got bored, saw what was currently the biggest issue facing the largest market concerns in Pharma today and said, "Hey, I think I can solve that problem". Yeah. Common sense should tell you what horse to bet on. Bet on Mick!
4 · Reply
Bigpapa46
Bigpapa46 Sep. 11 at 7:27 PM
$BMEA Finally a little action
0 · Reply
TheSuper
TheSuper Sep. 11 at 7:07 PM
$BMEA @CBARRR8 Nothing but worthless posts with 0 content of value. Must be upside down... I bet mom will let you move back to the basement.
2 · Reply
TheSuper
TheSuper Sep. 11 at 7:03 PM
$BMEA @CBARRR8 More than happy to debate you on your short theory.
0 · Reply
CBARRR8
CBARRR8 Sep. 11 at 6:34 PM
$BMEA The rise before the fall.
2 · Reply
Bigpapa46
Bigpapa46 Sep. 11 at 6:06 PM
$BMEA Huge difference from last fridays trading to today. 2hrs to go will buyers actually step up- shorts are starting to apply a little pressure
0 · Reply